3Thompson CA.Alosetron withdraw from market[J].Am J Health Syst Pharm,2001,58 (1):13.
4Miller DP,Alfredson T,Cook SF,et al.Incidence of colonic ischemia,hospitalized complications of constipation,and bowel surgery in relation to use of alosetron hydrochloride[J].AmJ Gastroenterol,2003,98(5):1117-1122.
5Bradette M,Moennikes H,Carter F,et al.Cilansetron in irritable bowel syndrome with diarrhea predominance (IBS-D):efficacy and safety in a 6 month global study[J].Gastroenterology.2004,126(suppl 2):A42.
6Tack J,Muller-Lissner S,Bytzer P,et al.A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation (IBS-C)[J].Gut,2005,10.1136.
7Read NW,Abitbol JL,Bardban KD,et al.Efficacv and safety of the peripheral kappa agonist fedozine versus Placebo in the treatment of functional dyspepsia[J].Gut,1997,41:664.
8Rodriguez LA,Ruigomez A.Increased risk of irritable bowel syndrome after bacterial gastroenteritis:cohort study[J].BMJ,1999,318:565-566.
10Balsari A,Ceccarelli A,Dubini F,et al.The fecal microbial population in the irritable bowel syndrome[J].Microbiologica,1982,5:185-194.
二级参考文献5
1Delvaux M, Wingate D. Trimebutine: mechanismof action, effects on gastrointestinal function and clinical results. J Int Med Res, 1997, 25: 225～246.
2Simon EJ. Opioid receptors and endogenous opi-oid peptides. Med Res Rev, 1991, 11: 357～374.
3Schang JC, Devroede G, Pilote M. Beneficial effects of trimebutine in patients suffering from irritable bowel disease with normal transit and constipation. Gastroenterology, 1988, 94: A403.
4Luttecke K. A three-part controlled study of trimebutine in the treatment of irritable colon syndrome. Curr Med Res Opin, 1980, 6: 437～443.
5Jinsong Liu, Xiaohua Hou. A review of the irritable bowel syndrome in- vestigation on epidemiology,pathogenesis and pathophysiology in Chi- na [ J ]. Journal of Gastroenterology and Hepatology, 2011,26, Supple- ment s3 : 88 - 93.
6Moore Communications, Ire. Breaktlwuugh in Patient Care for Irritable Bowel Syndrome[ C ]. sympotism update Glaxo Wellcorme,2000 : 156.
